€43.08
1.32% yesterday
Xetra, May 16, 05:35 pm CET
ISIN
DE0005785604
Symbol
FRE
Sector

Fresenius Stock price

€43.08
+3.58 9.06% 1M
+10.26 31.26% 6M
+9.54 28.44% YTD
+14.56 51.05% 1Y
+9.85 29.64% 3Y
+1.92 4.66% 5Y
-13.32 23.62% 10Y
Xetra, Closing price Fri, May 16 2025
+0.56 1.32%
ISIN
DE0005785604
Symbol
FRE
Sector

Key metrics

Market capitalization €24.26b
Enterprise Value €36.17b
P/E (TTM) P/E ratio 57.50
EV/FCF (TTM) EV/FCF 22.38
EV/Sales (TTM) EV/Sales 1.64
P/S ratio (TTM) P/S ratio 1.10
P/B ratio (TTM) P/B ratio 1.25
Dividend yield 2.32%
Last dividend (FY24) €1.00
Revenue growth (TTM) Revenue growth -18.90%
Revenue (TTM) Revenue €22.11b
EBIT (operating result TTM) EBIT €1.89b
Free Cash Flow (TTM) Free Cash Flow €1.62b
Cash position €2.39b
EPS (TTM) EPS €0.75
P/E forward 14.57
P/S forward 1.07
EV/Sales forward 1.59
Show more

Create a Free Account to create an Fresenius alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Fresenius Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Fresenius forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Fresenius forecast:

Buy
88%
Hold
12%

Financial data from Fresenius

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
22,107 22,107
19% 19%
100%
- Direct Costs 16,695 16,695
20% 20%
76%
5,412 5,412
14% 14%
24%
- Selling and Administrative Expenses 1,705 1,705
27% 27%
8%
- Research and Development Expense 642 642
10% 10%
3%
3,065 3,065
28% 28%
14%
- Depreciation and Amortization 1,175 1,175
39% 39%
5%
EBIT (Operating Income) EBIT 1,890 1,890
19% 19%
9%
Net Profit 422 422
164% 164%
2%

In millions EUR.

Don't miss a Thing! We will send you all news about Fresenius directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fresenius Stock News

AD HOC NEWS
one day ago
Deutsche Bank Research hat das Kursziel für Fresenius DE0005785604 von 49 auf 52 Euro angehoben und die Einstufung auf "Buy" belassen.
AD HOC NEWS
10 days ago
Der Krankenhaus- und Arzneimittelkonzern Fresenius DE0005785604 ist zum Jahresstart weiter gewachsen und hat dabei überraschend viel verdient.
AD HOC NEWS
10 days ago
Das Analysehaus Jefferies hat die Einstufung für Fresenius DE0005785604 mit einem Kursziel von 48 Euro auf "Buy" belassen.
More Fresenius News

Company Profile

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment comprises dialysis products and healthcare services. The Fresenius Kabi segment specializes intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios focuses on the private hospital operations. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The Corporate and Other segment includes the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Head office Germany
CEO Michael Sen
Employees 176,486
Founded 1912
Website www.fresenius.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today